This post was originally published on this site
Abbott’s Freestyle Libre has been driving its medical devices sales, offsetting a fall in the numbers of COVID-19 diagnostic tests as infections wane.
The company recorded $1.1 billion in sales of FreeStyle Libre, with the U.S. market recording a growth of more than 40%.
Excluding one-off items, the healthcare giant reported a profit of $1.03 per share for the fourth quarter ended Dec. 31, higher than analysts’ average estimate of 92 cents.
The company also announced an adjusted profit forecast of $4.30 to $4.50 per share for 2023.
